A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Clinical trial NCT07214662 · RECRUITING
Trial details
- NCT number
- NCT07214662
- Sponsor
- Genentech, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-13
- Primary completion
- 2030-06-01
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.